Our Pipeline

"We stand at the threshold of realizing the long unfulfilled promise of RNA medicine. Our rapidly advancing clinical programs in Duchenne muscular dystrophy, Marburg and influenza represent the foundation for a growing and diverse pipeline in rare and infectious diseases."

  • Chris Garabedian, President and Chief Executive Officer
 
 
 
 

Our therapeutic development programs include lead clinical candidates for Duchenne muscular dystrophy, hemorrhagic fever viruses and influenza.

  • PROGRAM
  • DISCOVERY
  • preclinical
  • PHASE 1
  • PHASE 2
  • PHASE 3
 

RARE DISEASES

  • ETEPLIRSEN (AVI-4658)
    DMD (EXON 51)
  • SRP-4053
    DMD (EXON 53)
  • SRP-4045
    DMD (EXON 45)
  • SRP-4050
    DMD (EXON 50)
  • SRP-4044
    DMD (EXON 44)
  • SRP-4052
    DMD (EXON 52)
  • SRP-4055
    DMD (EXON 55)
  • SRP-4008
    DMD (EXON 8)
  • UNDISCLOSED TARGETS
    NON-DMD
 
 

INFECTIOUS DISEASES

  • AVI-7288
    MARBURG VIRUS
  • AVI-7537
    EBOLA VIRUS
  • AVI-7100
    INFLUENZA
  • VIRAL PMO-X
    DENGUE
  • BACTERIAL PPMO
    TB
  • UNDISCLOSED TARGETS